Skip to main content

Table 3 Biomarker levels in the control group (conventional treatment) and in the intervention group (duration of antibiotic treatment based on IDSA / ATS), in the per-protocol analysis

From: Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia

  Control
n = 61
Intervention
n = 75
p value
ProADM day 1 1.01 (0.78, 1.32) 0.91 (0.68, 1.25) 0.41
ProADM day 5 0.81 (0.57, 1.01) 0.81 (0.54, 1.19) 0.59
ProADM day 30 0.70 (0.49, 1.01) 0.68 (0.49, 0.93) 0.93
ProADM difference from day 5 to day 30 −0.07 (−0.23, 0.01) −0.09 (−0.15, 0.03) 0.65
PCR day 1 240.20 (86.80, 301.30) 159.75 (87.75, 302.60) 0.47
PCR day 5 47.50 (25.10, 88.50) 37.10 (15.70, 79.30) 0.20
PCR day 30 2.55 (1.60, 7.80) 2.50 (1.30, 5.40) 0.48
PCR difference from day 5 to day 30 −42.30 (−86.70, −21.90) −32.45 (−73.35, −14.50) 0.17
PCT day 1 0.67 (0.18, 3.34) 0.49 (0.15, 1.68) 0.67
PCT day 5 0.19 (0.09, 0.50) 0.17 (0.06, 0.75) 0.87
PCT day 30 0.04 (0.02, 0.06) 0.04 (0.03, 0.06) 0.54
PCT difference from day 5 to day 30 −0.12 (−0.40, −0.04) −0.18 (− 0.69, − 0.03) 0.49
  1. Data are presented as median (IQR)
  2. IQR interquartile range